Literature DB >> 31924605

Flow-Diversion Treatment for Unruptured Nonsaccular Intracranial Aneurysms of the Posterior and Distal Anterior Circulation: A Meta-Analysis.

F Cagnazzo1, P-H Lefevre2, I Derraz2, C Dargazanli2, G Gascou2, D T di Carlo3, P Perrini3, R Ahmed2, J F Hak2, C Riquelme2, A Bonafe2, V Costalat2.   

Abstract

BACKGROUND: Treatment management and outcomes of unruptured nonsaccular aneurysms are different compared with their saccular counterparts.
PURPOSE: Our aim was to analyze the outcomes after flow diversion among nonsaccular unruptured lesions. DATA SOURCES: A systematic search of 3 data bases (2005-2019) was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. STUDY SELECTION: We included studies reporting flow diversion for nonsaccular unruptured aneurysms of the posterior and distal anterior circulations. Anterior circulation lesions were included if located distal to the petrocavernous and supraclinoid ICA (MCA, A1, anterior communicating artery, A2). Giant dolichoectatic holobasilar lesions were excluded because of their poor treatment outcomes. DATA ANALYSIS: Aneurysm occlusion and complication rates were calculated (random effects meta-analysis). DATA SYNTHESIS: We included 15 studies (213 aneurysms). The long-term adequate occlusion rate was 85.3% (137/168; 95% CI, 78.2%-92.4%; I2 = 42.3%). Treatment-related complications were 17.4% (41/213; 95% CI, 12.45%-22.4%; I2 = 0%). Overall, 15% (37/213; 95% CI, 10%-20%; I2 = 0%) were ischemic events. Procedure-related morbidity was 8% (20/213; 95% CI, 5%-12%; I2 = 0%). Fusiform or dissecting types had comparable adequate occlusion (116/146 = 83%; 95% CI, 74%-92%; I2 = 48% versus 33/36 = 89%; 95% CI, 80%-98%; I2 = 0%; P = .31) and complication rates (35/162 = 17%; 95% CI, 10%-25%; I2 = 24% versus 11/51 = 19%; 95% CI, 10%-31%; I2 = 0%; P = .72). Aneurysm size (>10 versus ≤10 mm) was independently associated with a higher rate of complications (OR = 6.6; 95% CI, 1.3-15; P = .02). The rate of ischemic events after discontinuation of the antiplatelet therapy was 5% (5/93; 95% CI, 2%-9%; I2 = 0%). LIMITATIONS: Small and retrospective studies were available for this meta-analysis.
CONCLUSIONS: Unruptured nonsaccular aneurysms located in the posterior and distal anterior circulations can be effectively treated with flow diversion. Nevertheless, treatment-related complications are not negligible, with about 15% ischemic events and 8% morbidity. Larger size (>10 mm) significantly increases the risk of procedure-related adverse events.
© 2020 by American Journal of Neuroradiology.

Entities:  

Mesh:

Year:  2020        PMID: 31924605      PMCID: PMC6975330          DOI: 10.3174/ajnr.A6352

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  30 in total

1.  Risk Factors for Ischemic Complications following Pipeline Embolization Device Treatment of Intracranial Aneurysms: Results from the IntrePED Study.

Authors:  W Brinjikji; G Lanzino; H J Cloft; A H Siddiqui; E Boccardi; S Cekirge; D Fiorella; R Hanel; P Jabbour; E Levy; D Lopes; P Lylyk; I Szikora; D F Kallmes
Journal:  AJNR Am J Neuroradiol       Date:  2016-04-21       Impact factor: 3.825

2.  Flow-Diversion Treatment of Unruptured Saccular Anterior Communicating Artery Aneurysms: A Systematic Review and Meta-Analysis.

Authors:  F Cagnazzo; N Limbucci; S Nappini; L Renieri; A Rosi; A Laiso; D Tiziano di Carlo; P Perrini; S Mangiafico
Journal:  AJNR Am J Neuroradiol       Date:  2019-02-14       Impact factor: 3.825

3.  Flow Diversion in Middle Cerebral Artery Aneurysms: Is It Really an All-Purpose Treatment?

Authors:  Osman Melih Topcuoglu; Erol Akgul; Ergun Daglioglu; Elif Dilara Topcuoglu; Ahmet Peker; Ilkay Akmangit; Deniz Belen; Anil Arat
Journal:  World Neurosurg       Date:  2015-12-23       Impact factor: 2.104

4.  Pipeline for uncoilable or failed aneurysms: results from a multicenter clinical trial.

Authors:  Tibor Becske; David F Kallmes; Isil Saatci; Cameron G McDougall; István Szikora; Giuseppe Lanzino; Christopher J Moran; Henry H Woo; Demetrius K Lopes; Aaron L Berez; Daniel J Cher; Adnan H Siddiqui; Elad I Levy; Felipe C Albuquerque; David J Fiorella; Zsolt Berentei; Miklós Marosfoi; Saruhan H Cekirge; Peter K Nelson
Journal:  Radiology       Date:  2013-02-15       Impact factor: 11.105

5.  Pipeline Embolization Device for Pericallosal Artery Aneurysms: A Retrospective Single Center Safety and Efficacy Study.

Authors:  Katyucia De Macedo Rodrigues; Anna Luisa Kühn; Takamitsu Tamura; Guilherme Dabus; Peter Kan; Miklos G Marosfoi; J Diego Lozano; Mary Perras; Christopher Brooks; Mary C Howk; Samuel Y Hou; David E Rex; Francesco Massari; Matthew J Gounis; Ajay K Wakhloo; Ajit S Puri
Journal:  Oper Neurosurg (Hagerstown)       Date:  2018-04-01       Impact factor: 2.703

6.  International retrospective study of the pipeline embolization device: a multicenter aneurysm treatment study.

Authors:  D F Kallmes; R Hanel; D Lopes; E Boccardi; A Bonafé; S Cekirge; D Fiorella; P Jabbour; E Levy; C McDougall; A Siddiqui; I Szikora; H Woo; F Albuquerque; H Bozorgchami; S R Dashti; J E Delgado Almandoz; M E Kelly; R Turner; B K Woodward; W Brinjikji; G Lanzino; P Lylyk
Journal:  AJNR Am J Neuroradiol       Date:  2014-10-29       Impact factor: 3.825

7.  Pipeline embolization of posterior circulation aneurysms: a multicenter study of 131 aneurysms.

Authors:  Christoph J Griessenauer; Christopher S Ogilvy; Nimer Adeeb; Adam A Dmytriw; Paul M Foreman; Hussain Shallwani; Nicola Limbucci; Salvatore Mangiafico; Ashish Kumar; Caterina Michelozzi; Timo Krings; Vitor Mendes Pereira; Charles C Matouk; Mark R Harrigan; Hakeem J Shakir; Adnan H Siddiqui; Elad I Levy; Leonardo Renieri; Thomas R Marotta; Christophe Cognard; Ajith J Thomas
Journal:  J Neurosurg       Date:  2018-05-04       Impact factor: 5.115

Review 8.  Endovascular treatment of intracranial aneurysms with flow diverters: a meta-analysis.

Authors:  Waleed Brinjikji; Mohammad H Murad; Giuseppe Lanzino; Harry J Cloft; David F Kallmes
Journal:  Stroke       Date:  2013-01-15       Impact factor: 7.914

Review 9.  Endovascular management of fusiform aneurysms in the posterior circulation: the era of flow diversion.

Authors:  Ahmed J Awad; Justin R Mascitelli; Reham R Haroun; Reade A De Leacy; Johanna T Fifi; J Mocco
Journal:  Neurosurg Focus       Date:  2017-06       Impact factor: 4.047

Review 10.  Treatment of Middle Cerebral Artery Aneurysms with Flow-Diverter Stents: A Systematic Review and Meta-Analysis.

Authors:  F Cagnazzo; D Mantilla; P-H Lefevre; C Dargazanli; G Gascou; V Costalat
Journal:  AJNR Am J Neuroradiol       Date:  2017-10-05       Impact factor: 3.825

View more
  4 in total

1.  Anterior Circulation Fusiform Aneurysms Have a Lower Occlusion Rate After Pipeline Embolization Device Treatment Than Posterior Circulation Fusiform Aneurysms: A Multicenter Cohort Study.

Authors:  Chao Xu; Pei Wu; Liang Zou; Shancai Xu; Bin Luo; Xinjian Yang; Huaizhang Shi
Journal:  Front Neurol       Date:  2022-06-02       Impact factor: 4.086

2.  Whether Intracranial Aneurysm Could Be Well Treated by Flow Diversion: A Comprehensive Meta-Analysis of Large-Sample Studies including Anterior and Posterior Circulation.

Authors:  Yingjin Wang; Changwei Yuan; Shengli Shen; Liqing Xu; Hongzhou Duan
Journal:  Biomed Res Int       Date:  2021-03-08       Impact factor: 3.411

3.  Endovascular Treatment of Anterior Circulation Aneurysms With the p64 Flow Modulation Device: Mid- and Long-Term Results in 617 Aneurysms From a Single Center.

Authors:  Marta Aguilar Pérez; Elina Henkes; Victoria Hellstern; Carmen Serna Candel; Christina Wendl; Hansjörg Bäzner; Oliver Ganslandt; Hans Henkes
Journal:  Oper Neurosurg (Hagerstown)       Date:  2021-03-15       Impact factor: 2.703

4.  Flow diversion effect of the leo braided stent for aneurysms in the posterior and distal anterior circulations: A multicenter cohort study.

Authors:  Yu Duan; Binbin Xu; Xuanfeng Qin; Renling Mao; Yuanyuan Hu; Bin Zhou; Jian Li; Gong Chen
Journal:  Front Neurol       Date:  2022-09-27       Impact factor: 4.086

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.